Has GRAIL Considered GALLERI as a Diagnostic Test for "Possible Cancer" e.g. weight loss

GRAIL has repeatedly and publicly described a second product direction called DAC — Diagnostic Aid for Cancer — aimed at patients with non-specific signs and symptoms plus clinical suspicion of cancer, distinct from Galleri’s main asymptomatic MCED screening use case.

The cleanest public highlight is GRAIL’s own current page: https://grail.com/diagnostic-aid-for-cancer/

“We are developing our diagnostic aid for cancer (‘DAC’) test to accelerate diagnostic resolution for patients with non-specific signs and symptoms, but with a clinical suspicion of cancer.”

GRAIL says DAC is intended to help physicians “aid diagnosis, achieve resolution more quickly, and avoid unnecessary workups,” and estimates that about 16 million U.S. patients present each year with such non-specific signs and symptoms.

The strongest SEC evidence is even more explicit. In GRAIL’s spinout registration materials, the company described DAC as a test to “accelerate diagnostic resolution” in patients with non-specific signs and symptoms but clinical suspicion of cancer. It also said the product was a medium- to longer-term objective, with launch dependent on factors including U.S. reimbursement requirements. In the same filing, GRAIL quantified the clinical/economic story: about 16 million U.S. patients with non-specific signs/symptoms; more than 70% undergo imaging, scoping, biopsies or other procedures; more than 25% take over four months to reach diagnosis after referral; and only about 4% ultimately have cancer.

So the public thesis was very close to what you described: use a blood-based multi-cancer signal and cancer-signal-origin result to triage or route patients earlier in the diagnostic workup, instead of sending them through serial, organ-specific workups. GRAIL’s 2023 ASCO release on SYMPLIFY said the test showed feasibility in helping clinicians decide the route of referral from primary care. It specifically named symptoms like weight loss, anemia, and abdominal pain, and quoted the need for tools that could expedite diagnosis and potentially avoid invasive or costly investigations.

The Lancet Oncology/SYMPLIFY press materials reinforce the same public narrative. SYMPLIFY enrolled over 6,000 symptomatic patients referred for urgent diagnostic follow-up for suspected cancer. GRAIL said the study suggested the MCED methylation platform could assist referral decisions from primary care; the commonly reported symptoms included unexpected weight loss, bowel-habit change, post-menopausal bleeding, rectal bleeding, abdominal pain, pain, dysphagia, and anemia.

GRAIL also funded/postered real-world work in U.S. nonspecific-signs/symptoms patients. That AACR 2023 poster listed NSSS such as weight loss, anemia, fatigue, pain, malaise, nonspecific abdominal symptoms, abnormal labs, abnormal LFTs, abnormal iron, abnormal platelets/WBCs, and argued that these symptoms may lack a clear diagnostic pathway, causing undirected or misdirected evaluation. The conclusion proposed that a multi-cancer detection test could help stratify cancer risk and direct diagnostic evaluation in NSSS patients.

There is also public evidence that GRAIL later pulled back. In August 2024, after its spinout and portfolio review, GRAIL announced a restructuring focused on the core MCED/Galleri opportunity and said it was substantially decreasing investment in product programs beyond Galleri, including diagnostic aid for cancer and MRD. The November 2024 10-Q repeats that GRAIL had reduced investment in products beyond Galleri, including DAC. Reuters summarized the same restructuring as a 350-job reduction and a focus on Galleri.

So, in blog/diligence prose, I’d say:

Public documents show that GRAIL pursued, for several years, a second major use case beyond asymptomatic MCED screening: a “Diagnostic Aid for Cancer” for patients with non-specific symptoms and clinical suspicion of cancer. The premise was that a blood-based multi-cancer signal and tissue-of-origin prediction could help physicians route patients faster and avoid long, serial, organ-specific workups. GRAIL supported this strategy with SYMPLIFY and with U.S. real-world NSSS studies. But public filings also show that after its 2024 spinout, GRAIL substantially decreased investment in DAC and refocused resources on Galleri/MCED, with U.S. reimbursement requirements named as one of the gating factors for DAC commercialization.

#

#

16M possible cancers vs $2m actual incident cancers, circa 8X for $614 test vs circa $400 CT-MRI.

The goal is praiseworthy.  

The public-health denominator is the problem. The United States diagnoses about 2.1 million cancers per year, excluding common non-melanoma skin cancers. The top 15 cancer types account for roughly 1.8 million of those cases. But a “possible cancer” indication may sweep in something like 16 million Americans with anemia, weight loss, fatigue, vague abdominal symptoms, abnormal labs, or other non-specific findings. That is not a cancer population; it is a vast diagnostic-anxiety population in which cancer is the minority outcome. For payers, that makes policy writing, utilization control, and evidence expectations far harder than the phrase “diagnostic aid” might suggest.